Pfizer shareholders may finally get the bargain of their dreams in Seagen.

The cancer drug maker's innovative approach makes it an attractive acquisition candidate for a pharmaceutical behemoth. According to reports, pharmaceutical giant Pfizer Inc. is negotiating an acquisition that would please the company's investors. The Wall Street Journal reported last night that the pharmaceutical company is in preliminary talks to buy Seagen Inc. for more than $30 billion, which would immediately add four approved can....